

Amendment to the Claims

1 - 43. (canceled)

44. (currently amended) A method for identifying an agonist of SEQ ID NO:2, the method comprising the steps of:

- a) contacting a test compound potential agonist with a cell expressing SEQ ID NO:2; and
- b) determining whether in the presence of the test compound potential agonist the signaling activity of SEQ ID NO:2 is increased relative to the activity of SEQ ID NO:2 in the absence of the test compound potential agonist
wherein the increased signaling activity identifies the test compound as an agonist.

45. (currently amended) A method for identifying an inverse agonist of SEQ ID NO:2, the method comprising the steps of:

- a) contacting a test compound potential inverse agonist with a cell expressing SEQ ID NO:2; and
- b) determining whether in the presence of the test compound potential inverse agonist the activity of SEQ ID NO:2 is decreased relative to the activity of SEQ ID NO:2 in the absence of the test compound potential inverse agonist, and is decreased in the presence of an endogenous ligand or agonist
wherein the decreased signaling activity identifies the test compound as an inverse agonist.

46. (currently amended) A method for identifying an antagonist of SEQ ID NO:2, the method comprising the steps of

- a) contacting a test compound potential antagonist with a cell expressing SEQ ID NO:2; and
- b) determining whether in the presence of the test compound and an endogenous ligand or agonist potential antagonist the signaling activity of SEQ ID NO:2 is decreased relative to the activity of SEQ ID NO:2 in the presence of an endogenous ligand or agonist
wherein the decreased signaling activity identifies the test compound as an antagonist.